{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:34:03Z","timestamp":1791196443776,"version":"4.1.0"},"publisher-location":"Berlin, Heidelberg","reference-count":235,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"value":"9783642386633","type":"print"},{"value":"9783642386640","type":"electronic"}],"license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013]]},"DOI":"10.1007\/978-3-642-38664-0_18","type":"book-chapter","created":{"date-parts":[[2013,10,3]],"date-time":"2013-10-03T06:57:23Z","timestamp":1380783443000},"page":"437-476","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Anti-inflammatory and Immunosuppressive Agents in PAH"],"prefix":"10.1007","author":[{"given":"Jolyane","family":"Meloche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Renard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steeve","family":"Provencher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,6]]},"reference":[{"key":"18_CR00181","unstructured":"Actelion Pharmaceuticals (2011) Tracleer [package insert]. Actelion Pharmaceuticals US, Inc., South San Francisco, CA"},{"key":"18_CR00182","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1126\/science.285.5436.2129","volume":"285","author":"J Aramburu","year":"1999","unstructured":"Aramburu J, Yaffe MB, Lopez-Rodriguez C et al (1999) Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. Science 285:2129\u20132133","journal-title":"Science"},{"key":"18_CR00183","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1183\/09031936.00164209","volume":"35","author":"SJ Arends","year":"2010","unstructured":"Arends SJ, Damoiseaux J, Duijvestijn A et al (2010) Prevalence of anti-endothelial cell antibodies in idiopathic pulmonary arterial hypertension. Eur Respir J 35:923\u2013925","journal-title":"Eur Respir J"},{"key":"18_CR00184","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1182\/blood.V93.12.4232","volume":"93","author":"G Ascherl","year":"1999","unstructured":"Ascherl G, Hohenadl C, Schatz O et al (1999) Infection with human immunodeficiency virus-1 increases expression of vascular endothelial cell growth factor in T cells: implications for acquired immunodeficiency syndrome-associated vasculopathy. Blood 93:4232\u20134241","journal-title":"Blood"},{"key":"18_CR00185","first-page":"414","volume":"17","author":"RA Asherson","year":"1990","unstructured":"Asherson RA (1990) Pulmonary hypertension in systemic lupus erythematosus. J Rheumatol 17:414\u2013415","journal-title":"J Rheumatol"},{"key":"18_CR00186","first-page":"1","volume":"13","author":"RA Asherson","year":"1986","unstructured":"Asherson RA, Oakley CM (1986) Pulmonary hypertension and systemic lupus erythematosus. J Rheumatol 13:1\u20135","journal-title":"J Rheumatol"},{"key":"18_CR00187","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1016\/j.jacc.2009.04.011","volume":"54","author":"DB Badesch","year":"2009","unstructured":"Badesch DB, Champion HC, Sanchez MA et al (2009) Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 54:S55\u2013S66","journal-title":"J Am Coll Cardiol"},{"key":"18_CR00188","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1164\/rccm.2106007","volume":"165","author":"K Balabanian","year":"2002","unstructured":"Balabanian K, Foussat A, Dorfmuller P et al (2002) CX(3)C chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit Care Med 165:1419\u20131425","journal-title":"Am J Respir Crit Care Med"},{"key":"18_CR00189","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1136\/ard.2004.025528","volume":"64","author":"L Barile-Fabris","year":"2005","unstructured":"Barile-Fabris L, Ariza-Andraca R, Olguin-Ortega L et al (2005) Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis 64:620\u2013625","journal-title":"Ann Rheum Dis"},{"key":"18_CR001810","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1183\/09031936.00014209","volume":"34","author":"A Barnier","year":"2009","unstructured":"Barnier A, Frachon I, Dewilde J et al (2009) Improvement of HIV-related pulmonary hypertension after the introduction of an antiretroviral therapy. Eur Respir J 34:277\u2013278","journal-title":"Eur Respir J"},{"issue":"17","key":"18_CR001811","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1007\/s00018-012-0950-4","volume":"69","author":"M Barrier","year":"2012","unstructured":"Barrier M, Meloche J, Jacob MH et al (2012) Today\u2019s and tomorrow\u2019s imaging and circulating biomarkers for pulmonary arterial hypertension. Cell Mol Life Sci 69(17):2805\u20132831","journal-title":"Cell Mol Life Sci"},{"key":"18_CR001812","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1136\/thx.54.4.372","volume":"54","author":"F Bellotto","year":"1999","unstructured":"Bellotto F, Chiavacci P, Laveder F et al (1999) Effective immunosuppressive therapy in a patient with primary pulmonary hypertension. Thorax 54:372\u2013374","journal-title":"Thorax"},{"key":"18_CR001813","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1159\/000097495","volume":"75","author":"D Bendayan","year":"2008","unstructured":"Bendayan D, Sarid R, Cohen A et al (2008) Absence of human herpesvirus 8 DNA sequences in lung biopsies from Israeli patients with pulmonary arterial hypertension. Respiration 75:155\u2013157","journal-title":"Respiration"},{"key":"18_CR001814","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1136\/ard.2007.070367","volume":"67","author":"G Bertsias","year":"2008","unstructured":"Bertsias G, Ioannidis JP, Boletis J et al (2008) EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 67:195\u2013205","journal-title":"Ann Rheum Dis"},{"key":"18_CR001815","first-page":"126","volume":"1","author":"A Bhargava","year":"1999","unstructured":"Bhargava A, Kumar A, Yuan N et al (1999) Monocrotaline induces interleukin-6 mRNA expression in rat lungs. Heart Dis 1:126\u2013132","journal-title":"Heart Dis"},{"key":"18_CR001816","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1183\/09031936.00095606","volume":"29","author":"KG Blyth","year":"2007","unstructured":"Blyth KG, Groenning BA, Mark PB et al (2007) NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension. Eur Respir J 29:737\u2013744","journal-title":"Eur Respir J"},{"key":"18_CR001817","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1378\/chest.08-0492","volume":"135","author":"HJ Bogaard","year":"2009","unstructured":"Bogaard HJ, Abe K, Vonk Noordegraaf A et al (2009a) The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest 135:794\u2013804","journal-title":"Chest"},{"key":"18_CR001818","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1161\/CIRCULATIONAHA.109.883843","volume":"120","author":"HJ Bogaard","year":"2009","unstructured":"Bogaard HJ, Natarajan R, Henderson SC et al (2009b) Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation 120:1951\u20131960","journal-title":"Circulation"},{"key":"18_CR001819","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1161\/CIRCIMAGING.110.963207","volume":"4","author":"S Bokhari","year":"2011","unstructured":"Bokhari S, Raina A, Rosenweig EB et al (2011) PET imaging may provide a novel biomarker and understanding of right ventricular dysfunction in patients with idiopathic pulmonary arterial hypertension. Circ Cardiovasc Imaging 4:641\u2013647","journal-title":"Circ Cardiovasc Imaging"},{"key":"18_CR001820","doi-asserted-by":"publisher","first-page":"11418","DOI":"10.1073\/pnas.0610467104","volume":"104","author":"S Bonnet","year":"2007","unstructured":"Bonnet S, Rochefort G, Sutendra G et al (2007) The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci USA 104:11418\u201311423","journal-title":"Proc Natl Acad Sci USA"},{"key":"18_CR001821","first-page":"66","volume":"83","author":"P Bouree","year":"1990","unstructured":"Bouree P, Piveteau J, Gerbal JL et al (1990) Pulmonary arterial hypertension due to bilharziasis. Apropos of a case due to Schistosoma haematobium having been cured by praziquantel. Bull Soc Pathol Exot 83:66\u201371","journal-title":"Bull Soc Pathol Exot"},{"key":"18_CR001822","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1615\/CritRevImmunol.v28.i2.20","volume":"28","author":"S Brode","year":"2008","unstructured":"Brode S, Cooke A (2008) Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide. Crit Rev Immunol 28:109\u2013126","journal-title":"Crit Rev Immunol"},{"key":"18_CR001823","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1183\/09031936.03.00006903","volume":"22","author":"TM Bull","year":"2003","unstructured":"Bull TM, Cool CD, Serls AE et al (2003) Primary pulmonary hypertension, Castleman\u2019s disease and human herpesvirus-8. Eur Respir J 22:403\u2013407","journal-title":"Eur Respir J"},{"key":"18_CR001824","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1161\/CIRCULATIONAHA.107.727289","volume":"118","author":"G Butrous","year":"2008","unstructured":"Butrous G, Ghofrani HA, Grimminger F (2008) Pulmonary vascular disease in the developing world. Circulation 118:1758\u20131766","journal-title":"Circulation"},{"key":"18_CR001825","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1097\/RLU.0b013e3182177389","volume":"36","author":"MM Can","year":"2011","unstructured":"Can MM, Kaymaz C, Tanboga IH et al (2011) Increased right ventricular glucose metabolism in patients with pulmonary arterial hypertension. Clin Nucl Med 36:743\u2013748","journal-title":"Clin Nucl Med"},{"key":"18_CR001826","first-page":"1275","volume":"26","author":"JR Carneiro","year":"1999","unstructured":"Carneiro JR, Sato EI (1999) Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol 26:1275\u20131279","journal-title":"J Rheumatol"},{"key":"18_CR001827","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1053\/sarh.2002.50011","volume":"32","author":"MM Cerinic","year":"2003","unstructured":"Cerinic MM, Valentini G, Sorano GG et al (2003) Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. Semin Arthritis Rheum 32:285\u2013295","journal-title":"Semin Arthritis Rheum"},{"key":"18_CR001828","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1002\/art.10361","volume":"46","author":"C Chizzolini","year":"2002","unstructured":"Chizzolini C, Raschi E, Rezzonico R et al (2002) Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum 46:1602\u20131613","journal-title":"Arthritis Rheum"},{"key":"18_CR001829","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1378\/chest.122.5.1668","volume":"122","author":"JW Chu","year":"2002","unstructured":"Chu JW, Kao PN, Faul JL et al (2002) High prevalence of autoimmune thyroid disease in pulmonary arterial hypertension. Chest 122:1668\u20131673","journal-title":"Chest"},{"key":"18_CR001830","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1378\/chest.10-0260","volume":"138","author":"L Chung","year":"2010","unstructured":"Chung L, Liu J, Parsons L et al (2010) Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 138:1383\u20131394","journal-title":"Chest"},{"key":"18_CR001831","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/art.1780360113","volume":"36","author":"PJ Clements","year":"1993","unstructured":"Clements PJ, Lachenbruch PA, Sterz M et al (1993) Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients. Arthritis Rheum 36:75\u201383","journal-title":"Arthritis Rheum"},{"key":"18_CR001832","first-page":"470","volume":"22","author":"F Cofan","year":"2002","unstructured":"Cofan F, Gutierrez R, Beardo P et al (2002) Interaction between sildenafil and calcineurin inhibitors in renal transplant recipients with erectile dysfunction. Nefrologia 22:470\u2013476","journal-title":"Nefrologia"},{"key":"18_CR001833","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.2165\/00003495-200767080-00004","volume":"67","author":"RK Coker","year":"2007","unstructured":"Coker RK (2007) Guidelines for the use of corticosteroids in the treatment of pulmonary sarcoidosis. Drugs 67:1139\u20131147","journal-title":"Drugs"},{"key":"18_CR001834","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1164\/rccm.200806-953OC","volume":"179","author":"R Condliffe","year":"2009","unstructured":"Condliffe R, Kiely DG, Peacock AJ et al (2009) Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 179:151\u2013157","journal-title":"Am J Respir Crit Care Med"},{"key":"18_CR001835","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/nm1097","volume":"10","author":"JR Conejo-Garcia","year":"2004","unstructured":"Conejo-Garcia JR, Benencia F, Courreges MC et al (2004) Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med 10:950\u2013958","journal-title":"Nat Med"},{"key":"18_CR001836","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1056\/NEJMoa031855","volume":"350","author":"G Contreras","year":"2004","unstructured":"Contreras G, Pardo V, Leclercq B et al (2004) Sequential therapies for proliferative lupus nephritis. N Engl J Med 350:971\u2013980","journal-title":"N Engl J Med"},{"key":"18_CR001837","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/S0046-8177(97)90032-0","volume":"28","author":"CD Cool","year":"1997","unstructured":"Cool CD, Kennedy D, Voelkel NF et al (1997) Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol 28:434\u2013442","journal-title":"Hum Pathol"},{"key":"18_CR001838","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa035115","volume":"349","author":"CD Cool","year":"2003","unstructured":"Cool CD, Rai PR, Yeager ME et al (2003) Expression of human herpesvirus 8 in primary pulmonary hypertension. N Engl J Med 349:1113\u20131122","journal-title":"N Engl J Med"},{"key":"18_CR001839","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1164\/rccm.200903-0355OC","volume":"181","author":"A Crosby","year":"2010","unstructured":"Crosby A, Jones FM, Southwood M et al (2010) Pulmonary vascular remodeling correlates with lung eggs and cytokines in murine schistosomiasis. Am J Respir Crit Care Med 181:279\u2013288","journal-title":"Am J Respir Crit Care Med"},{"key":"18_CR001840","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1164\/rccm.201101-0146OC","volume":"184","author":"A Crosby","year":"2011","unstructured":"Crosby A, Jones FM, Kolosionek E et al (2011) Praziquantel reverses pulmonary hypertension and vascular remodeling in murine schistosomiasis. Am J Respir Crit Care Med 184:467\u2013473","journal-title":"Am J Respir Crit Care Med"},{"key":"18_CR001841","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1084\/jem.20071008","volume":"205","author":"E Daley","year":"2008","unstructured":"Daley E, Emson C, Guignabert C et al (2008) Pulmonary arterial remodeling induced by a Th2 immune response. J Exp Med 205:361\u2013372","journal-title":"J Exp Med"},{"key":"18_CR001842","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.4269\/ajtmh.1983.32.1049","volume":"32","author":"MA de Almeida","year":"1983","unstructured":"de Almeida MA, Andrade ZA (1983) Effect of chemotherapy on experimental pulmonary schistosomiasis. Am J Trop Med Hyg 32:1049\u20131054","journal-title":"Am J Trop Med Hyg"},{"key":"18_CR001843","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1086\/303059","volume":"67","author":"Z Deng","year":"2000","unstructured":"Deng Z, Morse JH, Slager SL et al (2000) Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 67:737\u2013744","journal-title":"Am J Hum Genet"},{"key":"18_CR001844","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/rheumatology\/33.1.90","volume":"33","author":"CP Denton","year":"1994","unstructured":"Denton CP, Sweny P, Abdulla A et al (1994) Acute renal failure occurring in scleroderma treated with cyclosporin A: a report of three cases. Br J Rheumatol 33:90\u201392","journal-title":"Br J Rheumatol"},{"key":"18_CR001845","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1093\/rheumatology\/kep295","volume":"48","author":"CT Derk","year":"2009","unstructured":"Derk CT, Grace E, Shenin M et al (2009) A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology (Oxford) 48:1595\u20131599","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"18_CR001846","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1183\/09031936.00181410","volume":"39","author":"H Dib","year":"2011","unstructured":"Dib H, Tamby MC, Bussone G et al (2011) Targets of anti-endothelial cell antibodies in pulmonary hypertension and scleroderma. Eur Respir J 39(6):1405\u20131414","journal-title":"Eur Respir J"},{"key":"18_CR001847","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1161\/CIRCULATIONAHA.108.769646","volume":"117","author":"GP Diller","year":"2008","unstructured":"Diller GP, van Eijl S, Okonko DO et al (2008) Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension. Circulation 117:3020\u20133030","journal-title":"Circulation"},{"key":"18_CR001848","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/ajh.22050","volume":"86","author":"A Dispenzieri","year":"2011","unstructured":"Dispenzieri A (2011) POEMS syndrome: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 86:591\u2013601","journal-title":"Am J Hematol"},{"key":"18_CR001849","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1164\/ajrccm.165.4.2012112","volume":"165","author":"P Dorfmuller","year":"2002","unstructured":"Dorfmuller P, Zarka V, Durand-Gasselin I et al (2002) Chemokine RANTES in severe pulmonary arterial hypertension. Am J Respir Crit Care Med 165:534\u2013539","journal-title":"Am J Respir Crit Care Med"},{"key":"18_CR001850","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1183\/09031936.03.00038903","volume":"22","author":"P Dorfmuller","year":"2003","unstructured":"Dorfmuller P, Perros F, Balabanian K et al (2003) Inflammation in pulmonary arterial hypertension. Eur Respir J 22:358\u2013363","journal-title":"Eur Respir J"},{"key":"18_CR001851","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.humpath.2006.11.022","volume":"38","author":"P Dorfmuller","year":"2007","unstructured":"Dorfmuller P, Humbert M, Perros F et al (2007) Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol 38:893\u2013902","journal-title":"Hum Pathol"},{"key":"18_CR001852","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.jacc.2010.03.065","volume":"56","author":"CJ dos Santos Fernandes","year":"2010","unstructured":"dos Santos Fernandes CJ, Jardim CV, Hovnanian A et al (2010) Survival in schistosomiasis-associated pulmonary arterial hypertension. J Am Coll Cardiol 56:715\u2013720","journal-title":"J Am Coll Cardiol"},{"key":"18_CR001853","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1165\/rcmb.2010-0412OC","volume":"45","author":"JI Drake","year":"2011","unstructured":"Drake JI, Bogaard HJ, Mizuno S et al (2011) Molecular signature of a right heart failure program in chronic severe pulmonary hypertension. Am J Respir Cell Mol Biol 45:1239\u20131247","journal-title":"Am J Respir Cell Mol Biol"},{"key":"18_CR001854","unstructured":"Drugs.com (2010) Side effects and drug-drug interaction. Denver, CO. http:\/\/www.drugs.com, Updated: 2010"},{"key":"18_CR001855","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/sj.cdd.4401807","volume":"13","author":"T Efferth","year":"2006","unstructured":"Efferth T, Schwarzl SM, Smith J et al (2006) Role of glucose-6-phosphate dehydrogenase for oxidative stress and apoptosis. Cell Death Differ 13:527\u2013528, author reply 529\u2013530","journal-title":"Cell Death Differ"},{"key":"18_CR001856","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.4049\/jimmunol.150.10.4601","volume":"150","author":"H Ehrenreich","year":"1993","unstructured":"Ehrenreich H, Rieckmann P, Sinowatz F et al (1993) Potent stimulation of monocytic endothelin-1 production by HIV-1 glycoprotein 120. J Immunol 150:4601\u20134609","journal-title":"J Immunol"},{"key":"18_CR001857","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/345084a0","volume":"345","author":"B Ensoli","year":"1990","unstructured":"Ensoli B, Barillari G, Salahuddin SZ et al (1990) Tat protein of HIV-1 stimulates growth of cells derived from Kaposi\u2019s sarcoma lesions of AIDS patients. Nature 345:84\u201386","journal-title":"Nature"},{"key":"18_CR001858","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1053\/pcad.2002.129975","volume":"45","author":"KA Fagan","year":"2002","unstructured":"Fagan KA, Badesch DB (2002) Pulmonary hypertension associated with connective tissue disease. Prog Cardiovasc Dis 45:225\u2013234","journal-title":"Prog Cardiovasc Dis"},{"key":"18_CR001859","doi-asserted-by":"publisher","first-page":"50S","DOI":"10.1378\/chest.114.1_Supplement.50S","volume":"114","author":"M Fartoukh","year":"1998","unstructured":"Fartoukh M, Emilie D, Le Gall C et al (1998) Chemokine macrophage inflammatory protein-1alpha mRNA expression in lung biopsy specimens of primary pulmonary hypertension. Chest 114:50S\u201351S","journal-title":"Chest"},{"key":"18_CR001860","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1586\/ers.11.58","volume":"5","author":"CJ Fernandes","year":"2011","unstructured":"Fernandes CJ, Jardim CV, Hovnanian A et al (2011) Schistosomiasis and pulmonary hypertension. Expert Rev Respir Med 5:675\u2013681","journal-title":"Expert Rev Respir Med"},{"key":"18_CR001861","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1093\/rheumatology\/38.10.992","volume":"38","author":"G Filaci","year":"1999","unstructured":"Filaci G, Cutolo M, Scudeletti M et al (1999) Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12 months of therapy. Rheumatology (Oxford) 38:992\u2013996","journal-title":"Rheumatology (Oxford)"},{"key":"18_CR001862","first-page":"836","volume":"28","author":"E Fois","year":"2010","unstructured":"Fois E, Le Guern V, Dupuy A et al (2010) Noninvasive assessment of systolic pulmonary artery pressure in systemic lupus erythematosus: retrospective analysis of 93 patients. Clin Exp Rheumatol 28:836\u2013841","journal-title":"Clin Exp Rheumatol"},{"key":"18_CR001863","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1371\/journal.ppat.0030052","volume":"3","author":"TC Freitas","year":"2007","unstructured":"Freitas TC, Jung E, Pearce EJ (2007) TGF-beta signaling controls embryo development in the parasitic flatworm Schistosoma mansoni. PLoS Pathog 3:e52","journal-title":"PLoS Pathog"},{"key":"18_CR001864","first-page":"1688","volume":"22","author":"MJ Fritzler","year":"1995","unstructured":"Fritzler MJ, Hart DA, Wilson D et al (1995) Antibodies to fibrin bound tissue type plasminogen activator in systemic sclerosis. J Rheumatol 22:1688\u20131693","journal-title":"J Rheumatol"},{"key":"18_CR001865","doi-asserted-by":"crossref","first-page":"L39","DOI":"10.1152\/ajplung.2001.280.1.L39","volume":"280","author":"M Fujita","year":"2001","unstructured":"Fujita M, Shannon JM, Irvin CG et al (2001) Overexpression of tumor necrosis factor-alpha produces an increase in lung volumes and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 280:L39\u2013L49","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"18_CR001866","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1093\/eurheartj\/ehp297","volume":"30","author":"N Galie","year":"2009","unstructured":"Galie N, Hoeper MM, Humbert M et al (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30:2493\u20132537","journal-title":"Eur Heart J"},{"key":"18_CR001867","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1183\/09031936.00016006","volume":"28","author":"CT Gan","year":"2006","unstructured":"Gan CT, McCann GP, Marcus JT et al (2006) NT-proBNP reflects right ventricular structure and function in pulmonary hypertension. Eur Respir J 28:1190\u20131194","journal-title":"Eur Respir J"},{"issue":"10","key":"18_CR001868","doi-asserted-by":"publisher","first-page":"L1014","DOI":"10.1152\/ajplung.00357.2011","volume":"302","author":"EV Gerasimovskaya","year":"2012","unstructured":"Gerasimovskaya EV, Kratzer A, Sidiakova A et al (2012) Interplay of macrophages and T cells in the lung vasculature. Am J Physiol Lung Cell Mol Physiol 302(10):L1014\u2013L1022","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"18_CR001869","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1378\/chest.06-2861","volume":"133","author":"AJ Gerbino","year":"2008","unstructured":"Gerbino AJ, Goss CH, Molitor JA (2008) Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 133:455\u2013460","journal-title":"Chest"},{"key":"18_CR001870","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1111\/j.1476-5381.1989.tb12676.x","volume":"98","author":"M Goppelt-Struebe","year":"1989","unstructured":"Goppelt-Struebe M, Wolter D, Resch K (1989) Glucocorticoids inhibit prostaglandin synthesis not only at the level of phospholipase A2 but also at the level of cyclo-oxygenase\/PGE isomerase. Br J Pharmacol 98:1287\u20131295","journal-title":"Br J Pharmacol"},{"key":"18_CR001871","doi-asserted-by":"publisher","first-page":"R147","DOI":"10.1186\/ar2821","volume":"11","author":"P Gourh","year":"2009","unstructured":"Gourh P, Arnett FC, Assassi S et al (2009) Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther 11:R147","journal-title":"Arthritis Res Ther"},{"key":"18_CR001872","doi-asserted-by":"publisher","first-page":"20S","DOI":"10.1378\/chest.10-0048","volume":"137","author":"BB Graham","year":"2010","unstructured":"Graham BB, Bandeira AP, Morrell NW et al 2010) Schistosomiasis-associated pulmonary hypertension: pulmonary vascular disease: the global perspective. Chest 137:20S\u201329S","journal-title":"Chest"},{"key":"18_CR001873","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1046\/j.1365-2249.2000.01320.x","volume":"121","author":"B Grigolo","year":"2000","unstructured":"Grigolo B, Mazzetti I, Meliconi R et al (2000) Anti-topoisomerase II alpha autoantibodies in systemic sclerosis-association with pulmonary hypertension and HLA-B35. Clin Exp Immunol 121:539\u2013543","journal-title":"Clin Exp Immunol"},{"key":"18_CR001874","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1097\/01.TP.0000141227.63639.63","volume":"78","author":"JM Grinyo","year":"2004","unstructured":"Grinyo JM, Cruzado JM, Millan O et al (2004) Low-dose cyclosporine with mycophenolate mofetil induces similar calcineurin activity and cytokine inhibition as does standard-dose cyclosporine in stable renal allografts. Transplantation 78:1400\u20131403","journal-title":"Transplantation"},{"key":"18_CR001875","first-page":"1055","volume":"20","author":"H Groen","year":"1993","unstructured":"Groen H, Bootsma H, Postma DS et al (1993) Primary pulmonary hypertension in a patient with systemic lupus erythematosus: partial improvement with cyclophosphamide. J Rheumatol 20:1055\u20131057","journal-title":"J Rheumatol"},{"key":"18_CR001876","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1161\/01.RES.0000222546.45372.a0","volume":"98","author":"C Guignabert","year":"2006","unstructured":"Guignabert C, Izikki M, Tu LI et al (2006) Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ Res 98:1323\u20131330","journal-title":"Circ Res"},{"key":"18_CR001877","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.1096\/fj.09-131664","volume":"23","author":"C Guignabert","year":"2009","unstructured":"Guignabert C, Tu L, Izikki M et al (2009) Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22alpha-targeted overexpression of the serotonin transporter. FASEB J 23:4135\u20134147","journal-title":"FASEB J"},{"key":"18_CR001878","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.1002\/art.21433","volume":"52","author":"E Hachulla","year":"2005","unstructured":"Hachulla E, Gressin V, Guillevin L et al (2005) Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 52:3792\u20133800","journal-title":"Arthritis Rheum"},{"key":"18_CR001879","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1136\/ard.2008.095836","volume":"68","author":"AL Hachulla","year":"2009","unstructured":"Hachulla AL, Launay D, Gaxotte V et al (2009) Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. Ann Rheum Dis 68:1878\u20131884","journal-title":"Ann Rheum Dis"},{"key":"18_CR001880","doi-asserted-by":"publisher","first-page":"L1473","DOI":"10.1152\/ajplung.00197.2006","volume":"292","author":"M Hagen","year":"2007","unstructured":"Hagen M, Fagan K, Steudel W et al (2007) Interaction of interleukin-6 and the BMP pathway in pulmonary smooth muscle. Am J Physiol Lung Cell Mol Physiol 292:L1473\u2013L1479","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"18_CR001881","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1136\/thx.2008.106435","volume":"64","author":"S Hall","year":"2009","unstructured":"Hall S, Brogan P, Haworth SG et al (2009) Contribution of inflammation to the pathology of idiopathic pulmonary arterial hypertension in children. Thorax 64:778\u2013783","journal-title":"Thorax"},{"key":"18_CR001882","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1164\/ajrccm.160.4.9810058","volume":"160","author":"H Hamada","year":"1999","unstructured":"Hamada H, Terai M, Kimura H et al (1999) Increased expression of mast cell chymase in the lungs of patients with congenital heart disease associated with early pulmonary vascular disease. Am J Respir Crit Care Med 160:1303\u20131308","journal-title":"Am J Respir Crit Care Med"},{"key":"18_CR001883","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1001\/jama.300.5.555","volume":"300","author":"SM Hammer","year":"2008","unstructured":"Hammer SM, Eron JJ Jr, Reiss P et al (2008) Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 300:555\u2013570","journal-title":"JAMA"},{"key":"18_CR001884","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1055\/s-0029-1233312","volume":"30","author":"PM Hassoun","year":"2009","unstructured":"Hassoun PM (2009) Pulmonary arterial hypertension complicating connective tissue diseases. Semin Respir Crit Care Med 30:429\u2013439","journal-title":"Semin Respir Crit Care Med"},{"key":"18_CR001885","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.jacc.2009.04.006","volume":"54","author":"PM Hassoun","year":"2009","unstructured":"Hassoun PM, Mouthon L, Barbera JA et al (2009) Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 54:S10\u2013S19","journal-title":"J Am Coll Cardiol"},{"key":"18_CR001886","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1136\/jcp.44.12.1003","volume":"44","author":"D Heath","year":"1991","unstructured":"Heath D, Yacoub M (1991) Lung mast cells in plexogenic pulmonary arteriopathy. J Clin Pathol 44:1003\u20131006","journal-title":"J Clin Pathol"},{"key":"18_CR001887","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1002\/j.1460-2075.1992.tb05523.x","volume":"11","author":"CH Heldin","year":"1992","unstructured":"Heldin CH (1992) Structural and functional studies on platelet-derived growth factor. EMBO J 11:4251\u20134259","journal-title":"EMBO J"},{"key":"18_CR001888","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1164\/rccm.200504-546OC","volume":"172","author":"C Henke-Gendo","year":"2005","unstructured":"Henke-Gendo C, Mengel M, Hoeper MM et al (2005) Absence of Kaposi\u2019s sarcoma-associated herpesvirus in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 172:1581\u20131585","journal-title":"Am J Respir Crit Care Med"},{"key":"18_CR001889","first-page":"341","volume":"27","author":"T Henriques-Coelho","year":"2008","unstructured":"Henriques-Coelho T, Brandao-Nogueira A, Moreira-Goncalves D et al (2008) Effects of TNF-alpha blockade in monocrotaline-induced pulmonary hypertension. Rev Port Cardiol 27:341\u2013348","journal-title":"Rev Port Cardiol"},{"key":"18_CR001890","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1016\/j.rmed.2007.05.020","volume":"101","author":"GA Heresi","year":"2007","unstructured":"Heresi GA, Minai OA (2007) Lupus-associated pulmonary hypertension: long-term response to vasoactive therapy. Respir Med 101:2099\u20132107","journal-title":"Respir Med"},{"key":"18_CR001891","doi-asserted-by":"publisher","first-page":"48S","DOI":"10.1016\/j.jacc.2004.02.010","volume":"43","author":"MM Hoeper","year":"2004","unstructured":"Hoeper MM, Oudiz RJ, Peacock A et al (2004) End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol 43:48S\u201355S","journal-title":"J Am Coll Cardiol"},{"key":"18_CR001892","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.1002\/art.22204","volume":"54","author":"RK Hoyles","year":"2006","unstructured":"Hoyles RK, Ellis RW, Wellsbury J et al (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54:3962\u20133970","journal-title":"Arthritis Rheum"},{"key":"18_CR001893","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1097\/QAD.0b013e3282f7cd42","volume":"22","author":"PY Hsue","year":"2008","unstructured":"Hsue PY, Deeks SG, Farah HH et al (2008) Role of HIV and human herpesvirus-8 infection in pulmonary arterial hypertension. AIDS 22:825\u2013833","journal-title":"AIDS"},{"issue":"4","key":"18_CR001894","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1183\/09031936.00159911","volume":"40","author":"A Huertas","year":"2012","unstructured":"Huertas A, Tu L, Gambaryan N et al (2012) Leptin and regulatory T lymphocytes in idiopathic pulmonary arterial hypertension. Eur Respir J 40(4):895\u2013904","journal-title":"Eur Respir J"},{"issue":"Suppl 3","key":"18_CR001895","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1097\/01.aids.0000327515.55041.da","volume":"22","author":"M Humbert","year":"2008","unstructured":"Humbert M (2008) Mediators involved in HIV-related pulmonary arterial hypertension. AIDS 22(Suppl 3):S41\u2013S47","journal-title":"AIDS"},{"key":"18_CR001896","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1164\/ajrccm.151.5.7735624","volume":"151","author":"M Humbert","year":"1995","unstructured":"Humbert M, Monti G, Brenot F et al (1995) Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 151:1628\u20131631","journal-title":"Am J Respir Crit Care Med"},{"key":"18_CR001897","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1183\/09031936.98.11030554","volume":"11","author":"M Humbert","year":"1998","unstructured":"Humbert M, Monti G, Fartoukh M et al (1998) Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 11:554\u2013559","journal-title":"Eur Respir J"},{"key":"18_CR001898","doi-asserted-by":"publisher","first-page":"13S","DOI":"10.1016\/j.jacc.2004.02.029","volume":"43","author":"M Humbert","year":"2004","unstructured":"Humbert M, Morrell NW, Archer SL et al (2004) Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43:13S\u201324S","journal-title":"J Am Coll Cardiol"},{"key":"18_CR001899","doi-asserted-by":"publisher","first-page":"15","DOI":"10.5551\/jat.11.15","volume":"11","author":"T Imaizumi","year":"2004","unstructured":"Imaizumi T, Yoshida H, Satoh K (2004) Regulation of CX3CL1\/fractalkine expression in endothelial cells. J Atheroscler Thromb 11:15\u201321","journal-title":"J Atheroscler Thromb"},{"key":"18_CR0018100","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/art.23303","volume":"58","author":"X Jais","year":"2008","unstructured":"Jais X, Launay D, Yaici A et al (2008) Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum 58:521\u2013531","journal-title":"Arthritis Rheum"},{"key":"18_CR0018101","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.rmed.2006.04.026","volume":"101","author":"P Jouve","year":"2007","unstructured":"Jouve P, Humbert M, Chauveheid MP et al (2007) POEMS syndrome-related pulmonary hypertension is steroid-responsive. Respir Med 101:353\u2013355","journal-title":"Respir Med"},{"key":"18_CR0018102","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1136\/ard.55.8.561","volume":"55","author":"M Karmochkine","year":"1996","unstructured":"Karmochkine M, Wechsler B, Godeau P et al (1996) Improvement of severe pulmonary hypertension in a patient with SLE. Ann Rheum Dis 55:561\u2013562","journal-title":"Ann Rheum Dis"},{"key":"18_CR0018103","first-page":"L100","volume":"264","author":"D Katayose","year":"1993","unstructured":"Katayose D, Ohe M, Yamauchi K et al (1993) Increased expression of PDGF A- and B-chain genes in rat lungs with hypoxic pulmonary hypertension. Am J Physiol 264:L100\u2013L106","journal-title":"Am J Physiol"},{"key":"18_CR0018104","first-page":"510","volume":"16","author":"Y Kawaguchi","year":"1998","unstructured":"Kawaguchi Y, Hara M, Harigai M et al (1998) Corticosteroid pulse therapy in a patient with SLE and pulmonary hypertension. Clin Exp Rheumatol 16:510","journal-title":"Clin Exp Rheumatol"},{"key":"18_CR0018105","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1378\/chest.123.2.344","volume":"123","author":"SM Kawut","year":"2003","unstructured":"Kawut SM, Taichman DB, Archer-Chicko CL et al (2003) Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 123:344\u2013350","journal-title":"Chest"},{"issue":"1","key":"18_CR0018106","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s12016-011-8265-z","volume":"44","author":"N Kherbeck","year":"2011","unstructured":"Kherbeck N, Tamby MC, Bussone G et al (2011) The role of inflammation and autoimmunity in the pathophysiology of pulmonary arterial hypertension. Clin Rev Allergy Immunol 44(1):31\u201338","journal-title":"Clin Rev Allergy Immunol"},{"key":"18_CR0018107","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.actatropica.2009.11.012","volume":"113","author":"CH King","year":"2010","unstructured":"King CH (2010) Parasites and poverty: the case of schistosomiasis. Acta Trop 113:95\u2013104","journal-title":"Acta Trop"},{"key":"18_CR0018108","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1292\/jvms.69.887","volume":"69","author":"T Kobayashi","year":"2007","unstructured":"Kobayashi T, Momoi Y, Iwasaki T (2007) Cyclosporine A inhibits the mRNA expressions of IL-2, IL-4 and IFN-gamma, but not TNF-alpha, in canine mononuclear cells. J Vet Med Sci 69:887\u2013892","journal-title":"J Vet Med Sci"},{"key":"18_CR0018109","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/nature06309","volume":"450","author":"CM Koebel","year":"2007","unstructured":"Koebel CM, Vermi W, Swann JB et al (2007) Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450:903\u2013907","journal-title":"Nature"},{"key":"18_CR0018110","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1164\/rccm.200512-1976OC","volume":"174","author":"N Koulmann","year":"2006","unstructured":"Koulmann N, Novel-Chate V, Peinnequin A et al (2006) Cyclosporin A inhibits hypoxia-induced pulmonary hypertension and right ventricle hypertrophy. Am J Respir Crit Care Med 174:699\u2013705","journal-title":"Am J Respir Crit Care Med"},{"key":"18_CR0018111","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1136\/ard.2008.096677","volume":"68","author":"O Kowal-Bielecka","year":"2009","unstructured":"Kowal-Bielecka O, Landewe R, Avouac J et al (2009) EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 68:620\u2013628","journal-title":"Ann Rheum Dis"},{"key":"18_CR0018112","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.amjmed.2004.03.039","volume":"117","author":"CA Labarrere","year":"2004","unstructured":"Labarrere CA, Zaloga GP (2004) C-reactive protein: from innocent bystander to pivotal mediator of atherosclerosis. Am J Med 117:499\u2013507","journal-title":"Am J Med"},{"key":"18_CR0018113","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0001-706X(00)00124-8","volume":"77","author":"JR Lambertucci","year":"2000","unstructured":"Lambertucci JR, Serufo JC, Gerspacher-Lara R et al (2000) Schistosoma mansoni: assessment of morbidity before and after control. Acta Trop 77:101\u2013109","journal-title":"Acta Trop"},{"key":"18_CR0018114","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/79226","volume":"26","author":"KB Lane","year":"2000","unstructured":"Lane KB, Machado RD, Pauciulo MW et al (2000) Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 26:81\u201384","journal-title":"Nat Genet"},{"key":"18_CR0018115","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1161\/CIRCULATIONAHA.108.803221","volume":"119","author":"M Lapa","year":"2009","unstructured":"Lapa M, Dias B, Jardim C et al (2009) Cardiopulmonary manifestations of hepatosplenic schistosomiasis. Circulation 119:1518\u20131523","journal-title":"Circulation"},{"key":"18_CR0018116","first-page":"223","volume":"23","author":"D Launay","year":"2006","unstructured":"Launay D, Souza R, Guillevin L et al (2006) Pulmonary arterial hypertension in ANCA-associated vasculitis. Sarcoidosis Vasc Diffuse Lung Dis 23:223\u2013228","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"18_CR0018117","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/MD.0b013e3181579781","volume":"86","author":"D Launay","year":"2007","unstructured":"Launay D, Hachulla E, Hatron PY et al (2007) Pulmonary arterial hypertension: a rare complication of primary Sjogren syndrome: report of 9 new cases and review of the literature. Medicine (Baltimore) 86:299\u2013315","journal-title":"Medicine (Baltimore)"},{"key":"18_CR0018118","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1164\/rccm.200909-1331PP","volume":"181","author":"J Le Pavec","year":"2011","unstructured":"Le Pavec J, Humbert M, Mouthon L et al (2011) Systemic sclerosis-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 181:1285\u20131293","journal-title":"Am J Respir Crit Care Med"},{"key":"18_CR0018119","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1164\/ajrccm.157.3.9707095","volume":"157","author":"P Lesprit","year":"1998","unstructured":"Lesprit P, Godeau B, Authier FJ et al (1998) Pulmonary hypertension in POEMS syndrome: a new feature mediated by cytokines. Am J Respir Crit Care Med 157:907\u2013911","journal-title":"Am J Respir Crit Care Med"},{"key":"18_CR0018120","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1067\/mai.2003.97","volume":"111","author":"DY Leung","year":"2003","unstructured":"Leung DY, Bloom JW (2003) Update on glucocorticoid action and resistance. J Allergy Clin Immunol 111:3\u201322, quiz 23","journal-title":"J Allergy Clin Immunol"},{"key":"18_CR0018121","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1378\/chest.10-1146","volume":"139","author":"JM Lorenzen","year":"2011","unstructured":"Lorenzen JM, Nickel N, Kramer R et al (2011) Osteopontin in patients with idiopathic pulmonary hypertension. Chest 139:1010\u20131017","journal-title":"Chest"},{"key":"18_CR0018122","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1056\/NEJM200003163421103","volume":"342","author":"DJ Lovell","year":"2000","unstructured":"Lovell DJ, Giannini EH, Reiff A et al (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 342:763\u2013769","journal-title":"N Engl J Med"},{"key":"18_CR0018123","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1056\/NEJM199802123380706","volume":"338","author":"AD Luster","year":"1998","unstructured":"Luster AD (1998) Chemokines \u2013 chemotactic cytokines that mediate inflammation. N Engl J Med 338:436\u2013445","journal-title":"N Engl J Med"},{"key":"18_CR0018124","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1086\/316947","volume":"68","author":"RD Machado","year":"2001","unstructured":"Machado RD, Pauciulo MW, Thomson JR et al (2001) BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 68:92\u2013102","journal-title":"Am J Hum Genet"},{"key":"18_CR0018125","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nri1632","volume":"5","author":"F Macian","year":"2005","unstructured":"Macian F (2005) NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol 5:472\u2013484","journal-title":"Nat Rev Immunol"},{"key":"18_CR0018126","doi-asserted-by":"crossref","unstructured":"Mandagere A, Core B, Bird S, Bingham J, Boinpally R (2010) Absence of a clinically relevant pharmacokinetic interaction between ambrisentan and mycophenolate mofetil. In: American Journal of Respiratory and Critical Care Medicine. American Thoracic Society International Conference, New Orleans, LA, USA","DOI":"10.1164\/ajrccm-conference.2010.181.1_MeetingAbstracts.A3356"},{"key":"18_CR0018127","doi-asserted-by":"publisher","first-page":"863","DOI":"10.2217\/imt.10.69","volume":"2","author":"R Manno","year":"2010","unstructured":"Manno R, Boin F (2010) Immunotherapy of systemic sclerosis. Immunotherapy 2:863\u2013878","journal-title":"Immunotherapy"},{"key":"18_CR0018128","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1055\/s-2007-985612","volume":"28","author":"W Marder","year":"2007","unstructured":"Marder W, McCune WJ (2007) Advances in immunosuppressive therapy. Semin Respir Crit Care Med 28:398\u2013417","journal-title":"Semin Respir Crit Care Med"},{"key":"18_CR0018129","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1586\/ers.11.18","volume":"5","author":"SC Mathai","year":"2011","unstructured":"Mathai SC, Hassoun PM (2011) Pulmonary arterial hypertension associated with systemic sclerosis. Expert Rev Respir Med 5:267\u2013279","journal-title":"Expert Rev Respir Med"},{"key":"18_CR0018130","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/art.24267","volume":"60","author":"SC Mathai","year":"2009","unstructured":"Mathai SC, Hummers LK, Champion HC et al (2009) Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 60:569\u2013577","journal-title":"Arthritis Rheum"},{"key":"18_CR0018131","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1056\/NEJM198806023182203","volume":"318","author":"WJ McCune","year":"1988","unstructured":"McCune WJ, Golbus J, Zeldes W et al (1988) Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med 318:1423\u20131431","journal-title":"N Engl J Med"},{"key":"18_CR0018132","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1172\/JCI24144","volume":"115","author":"TA McKinsey","year":"2005","unstructured":"McKinsey TA, Olson EN (2005) Toward transcriptional therapies for the failing heart: chemical screens to modulate genes. J Clin Invest 115:538\u2013546","journal-title":"J Clin Invest"},{"key":"18_CR0018133","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1161\/01.RES.0000145360.16770.9f","volume":"95","author":"MS McMurtry","year":"2004","unstructured":"McMurtry MS, Bonnet S, Wu X et al (2004) Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res 95:830\u2013840","journal-title":"Circ Res"},{"key":"18_CR0018134","doi-asserted-by":"publisher","first-page":"L933","DOI":"10.1152\/ajplung.00310.2006","volume":"293","author":"MS McMurtry","year":"2007","unstructured":"McMurtry MS, Bonnet S, Michelakis ED et al (2007) Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamycin-atorvastatin-simvastatin study. Am J Physiol Lung Cell Mol Physiol 293:L933\u2013L940","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"18_CR0018135","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1378\/chest.118.4.1133","volume":"118","author":"NJ Mehta","year":"2000","unstructured":"Mehta NJ, Khan IA, Mehta RN et al (2000) HIV-Related pulmonary hypertension: analytic review of 131 cases. Chest 118:1133\u20131141","journal-title":"Chest"},{"key":"18_CR0018136","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1161\/hc0202.101974","volume":"105","author":"ED Michelakis","year":"2002","unstructured":"Michelakis ED, McMurtry MS, Wu XC et al (2002) Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels. Circulation 105:244\u2013250","journal-title":"Circulation"},{"key":"18_CR0018137","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1177\/0961203309102822","volume":"18","author":"OA Minai","year":"2009","unstructured":"Minai OA (2009) Pulmonary hypertension in polymyositis-dermatomyositis: clinical and hemodynamic characteristics and response to vasoactive therapy. Lupus 18:1006\u20131010","journal-title":"Lupus"},{"key":"18_CR0018138","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1183\/09031936.05.00133904","volume":"26","author":"D Montani","year":"2005","unstructured":"Montani D, Achouh L, Marcelin AG et al (2005a) Reversibility of pulmonary arterial hypertension in HIV\/HHV8-associated Castleman\u2019s disease. Eur Respir J 26:969\u2013972","journal-title":"Eur Respir J"},{"key":"18_CR0018139","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1097\/01.aids.0000176230.94226.06","volume":"19","author":"D Montani","year":"2005","unstructured":"Montani D, Marcelin AG, Sitbon O et al (2005b) Human herpes virus 8 in HIV and non-HIV infected patients with pulmonary arterial hypertension in France. AIDS 19:1239\u20131240","journal-title":"AIDS"},{"key":"18_CR0018140","doi-asserted-by":"publisher","first-page":"e614","DOI":"10.1161\/CIRCULATIONAHA.110.991596","volume":"123","author":"D Montani","year":"2011","unstructured":"Montani D, Humbert M, Souza R (2011) Letter by Montani et al regarding article, \u201cElevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension\u201d. Circulation 123:e614, author reply e615","journal-title":"Circulation"},{"key":"18_CR0018141","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1177\/096120339300200606","volume":"2","author":"S Morelli","year":"1993","unstructured":"Morelli S, Giordano M, De Marzio P et al (1993) Pulmonary arterial hypertension responsive to immunosuppressive therapy in systemic lupus erythematosus. Lupus 2:367\u2013369","journal-title":"Lupus"},{"key":"18_CR0018142","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1164\/ajrccm.155.1.9001324","volume":"155","author":"JH Morse","year":"1997","unstructured":"Morse JH, Barst RJ, Fotino M et al (1997) Primary pulmonary hypertension, tissue plasminogen activator antibodies, and HLA-DQ7. Am J Respir Crit Care Med 155:274\u2013278","journal-title":"Am J Respir Crit Care Med"},{"key":"18_CR0018143","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1183\/09031936.05.00112105","volume":"26","author":"L Mouthon","year":"2005","unstructured":"Mouthon L, Guillevin L, Humbert M (2005) Pulmonary arterial hypertension: an autoimmune disease? Eur Respir J 26:986\u2013988","journal-title":"Eur Respir J"},{"key":"18_CR0018144","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1258\/jrsm.96.8.403","volume":"96","author":"D Mukerjee","year":"2003","unstructured":"Mukerjee D, Kingdon E, Vanderpump M et al (2003a) Pathophysiological insights from a case of reversible pulmonary arterial hypertension. J R Soc Med 96:403\u2013404","journal-title":"J R Soc Med"},{"key":"18_CR0018145","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1136\/ard.62.11.1088","volume":"62","author":"D Mukerjee","year":"2003","unstructured":"Mukerjee D, St George D, Coleiro B et al (2003b) Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 62:1088\u20131093","journal-title":"Ann Rheum Dis"},{"key":"18_CR0018146","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1089\/jir.2006.26.661","volume":"26","author":"D Mutschler","year":"2006","unstructured":"Mutschler D, Wikstrom G, Lind L et al (2006) Etanercept reduces late endotoxin-induced pulmonary hypertension in the pig. J Interferon Cytokine Res 26:661\u2013667","journal-title":"J Interferon Cytokine Res"},{"key":"18_CR0018147","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10067-005-1157-y","volume":"25","author":"O Nadashkevich","year":"2006","unstructured":"Nadashkevich O, Davis P, Fritzler M et al (2006) A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 25:205\u2013212","journal-title":"Clin Rheumatol"},{"key":"18_CR0018148","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1161\/01.CIR.102.8.865","volume":"102","author":"N Nagaya","year":"2000","unstructured":"Nagaya N, Nishikimi T, Uematsu M et al (2000) Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102:865\u2013870","journal-title":"Circulation"},{"key":"18_CR0018149","doi-asserted-by":"publisher","first-page":"R124","DOI":"10.1186\/ar2534","volume":"10","author":"C Nannini","year":"2008","unstructured":"Nannini C, West CP, Erwin PJ et al (2008) Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 10:R124","journal-title":"Arthritis Res Ther"},{"key":"18_CR0018150","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/nature01320","volume":"420","author":"C Nathan","year":"2002","unstructured":"Nathan C (2002) Points of control in inflammation. Nature 420:846\u2013852","journal-title":"Nature"},{"key":"18_CR0018151","first-page":"462","volume":"25","author":"VS Negi","year":"1998","unstructured":"Negi VS, Tripathy NK, Misra R et al (1998) Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. J Rheumatol 25:462\u2013466","journal-title":"J Rheumatol"},{"key":"18_CR0018152","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1183\/09031936.05.00045705","volume":"26","author":"MR Nicolls","year":"2005","unstructured":"Nicolls MR, Taraseviciene-Stewart L, Rai PR et al (2005) Autoimmunity and pulmonary hypertension: a perspective. Eur Respir J 26:1110\u20131118","journal-title":"Eur Respir J"},{"key":"18_CR0018153","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1164\/ajrccm.163.2.2006093","volume":"163","author":"T Nishimura","year":"2001","unstructured":"Nishimura T, Faul JL, Berry GJ et al (2001) 40-O-(2-hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respir Crit Care Med 163:498\u2013502","journal-title":"Am J Respir Crit Care Med"},{"key":"18_CR0018154","doi-asserted-by":"publisher","first-page":"e7956","DOI":"10.1371\/journal.pone.0007956","volume":"4","author":"X Niu","year":"2009","unstructured":"Niu X, Nouraie M, Campbell A et al (2009) Angiogenic and inflammatory markers of cardiopulmonary changes in children and adolescents with sickle cell disease. PLoS One 4:e7956","journal-title":"PLoS One"},{"key":"18_CR0018155","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1164\/rccm.200204-330OC","volume":"167","author":"H Nunes","year":"2003","unstructured":"Nunes H, Humbert M, Sitbon O et al (2003) Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 167:1433\u20131439","journal-title":"Am J Respir Crit Care Med"},{"key":"18_CR0018156","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1136\/thx.2005.042838","volume":"61","author":"H Nunes","year":"2006","unstructured":"Nunes H, Humbert M, Capron F et al (2006) Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 61:68\u201374","journal-title":"Thorax"},{"key":"18_CR0018157","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1161\/CIRCULATIONAHA.105.536169","volume":"112","author":"A Ogawa","year":"2005","unstructured":"Ogawa A, Nakamura K, Matsubara H et al (2005) Prednisolone inhibits proliferation of cultured pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension. Circulation 112:1806\u20131812","journal-title":"Circulation"},{"key":"18_CR0018158","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1164\/ajrccm.183.1.139","volume":"183","author":"A Ogawa","year":"2011","unstructured":"Ogawa A, Nakamura K, Mizoguchi H et al (2011) Prednisolone ameliorates idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 183:139\u2013140","journal-title":"Am J Respir Crit Care Med"},{"key":"18_CR0018159","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/art.1780350114","volume":"35","author":"Y Okano","year":"1992","unstructured":"Okano Y, Steen VD, Medsger TA Jr (1992) Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis. Arthritis Rheum 35:95\u2013100","journal-title":"Arthritis Rheum"},{"issue":"Suppl 3","key":"18_CR0018160","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1097\/01.aids.0000327514.60879.47","volume":"22","author":"M Opravil","year":"2008","unstructured":"Opravil M, Sereni D (2008) Natural history of HIV-associated pulmonary arterial hypertension: trends in the HAART era. AIDS 22(Suppl 3):S35\u2013S40","journal-title":"AIDS"},{"key":"18_CR0018161","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1164\/ajrccm.155.3.9117037","volume":"155","author":"M Opravil","year":"1997","unstructured":"Opravil M, Pechere M, Speich R et al (1997) HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med 155:990\u2013995","journal-title":"Am J Respir Crit Care Med"},{"key":"18_CR0018162","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1183\/09031936.00135407","volume":"31","author":"MJ Overbeek","year":"2008","unstructured":"Overbeek MJ, Lankhaar JW, Westerhof N et al (2008) Right ventricular contractility in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. Eur Respir J 31:1160\u20131166","journal-title":"Eur Respir J"},{"key":"18_CR0018163","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1073\/pnas.0408506102","volume":"102","author":"AK Palucka","year":"2005","unstructured":"Palucka AK, Blanck JP, Bennett L et al (2005) Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci USA 102:3372\u20133377","journal-title":"Proc Natl Acad Sci USA"},{"key":"18_CR0018164","doi-asserted-by":"publisher","first-page":"H1798","DOI":"10.1152\/ajpheart.00654.2011","volume":"301","author":"R Paulin","year":"2011","unstructured":"Paulin R, Meloche J, Jacob MH et al (2011) Dehydroepiandrosterone inhibits the Src\/STAT3 constitutive activation in pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol 301:H1798\u2013H1809","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"18_CR0018165","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1177\/000331979804901206","volume":"49","author":"AM Pellicelli","year":"1998","unstructured":"Pellicelli AM, Palmieri F, D\u2019Ambrosio C et al (1998) Role of human immunodeficiency virus in primary pulmonary hypertension \u2013 case reports. Angiology 49:1005\u20131011","journal-title":"Angiology"},{"key":"18_CR0018166","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1183\/09031936.00094706","volume":"29","author":"F Perros","year":"2007","unstructured":"Perros F, Dorfmuller P, Souza R et al (2007) Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension. Eur Respir J 29:462\u2013468","journal-title":"Eur Respir J"},{"issue":"Suppl 1","key":"18_CR0018167","doi-asserted-by":"publisher","first-page":"1S3","DOI":"10.1016\/S0755-4982(11)70002-1","volume":"40","author":"F Perros","year":"2011","unstructured":"Perros F, Montani D, Dorfmuller P et al (2011) [Novel immunopathological approaches to pulmonary arterial hypertension]. Presse Med 40(Suppl 1):1S3\u20131S13","journal-title":"Presse Med"},{"key":"18_CR0018168","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1164\/rccm.201105-0927OC","volume":"185","author":"F Perros","year":"2012","unstructured":"Perros F, Dorfmuller P, Montani D et al (2012) Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 185:311\u2013321","journal-title":"Am J Respir Crit Care Med"},{"key":"18_CR0018169","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00109-009-0524-6","volume":"88","author":"L Piao","year":"2010","unstructured":"Piao L, Fang YH, Cadete VJ et al (2010a) The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle. J Mol Med (Berl) 88:47\u201360","journal-title":"J Mol Med (Berl)"},{"key":"18_CR0018170","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s00109-010-0679-1","volume":"88","author":"L Piao","year":"2010","unstructured":"Piao L, Marsboom G, Archer SL (2010b) Mitochondrial metabolic adaptation in right ventricular hypertrophy and failure. J Mol Med (Berl) 88:1011\u20131020","journal-title":"J Mol Med (Berl)"},{"key":"18_CR0018171","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/BF02032091","volume":"1","author":"A Pines","year":"1982","unstructured":"Pines A, Kaplinsky N, Goldhammer E et al (1982) Corticosteroid responsive pulmonary hypertension in systemic lupus erythematosus. Clin Rheumatol 1:301\u2013304","journal-title":"Clin Rheumatol"},{"key":"18_CR0018172","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1177\/0961203307087188","volume":"17","author":"J Pope","year":"2008","unstructured":"Pope J (2008) An update in pulmonary hypertension in systemic lupus erythematosus \u2013 do we need to know about it? Lupus 17:274\u2013277","journal-title":"Lupus"},{"key":"18_CR0018173","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I","volume":"44","author":"JE Pope","year":"2001","unstructured":"Pope JE, Bellamy N, Seibold JR et al (2001) A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 44:1351\u20131358","journal-title":"Arthritis Rheum"},{"key":"18_CR0018174","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1183\/09031936.00028310","volume":"37","author":"LC Price","year":"2011","unstructured":"Price LC, Montani D, Tcherakian C et al (2011) Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats. Eur Respir J 37:813\u2013822","journal-title":"Eur Respir J"},{"key":"18_CR0018175","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1378\/chest.11-0793","volume":"141","author":"LC Price","year":"2012","unstructured":"Price LC, Wort SJ, Perros F et al (2012) Inflammation in pulmonary arterial hypertension. Chest 141:210\u2013221","journal-title":"Chest"},{"key":"18_CR0018176","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1469-0691.2010.03285.x","volume":"17","author":"SS Pullamsetti","year":"2011","unstructured":"Pullamsetti SS, Savai R, Janssen W et al (2011) Inflammation, immunological reaction and role of infection in pulmonary hypertension. Clin Microbiol Infect 17:7\u201314","journal-title":"Clin Microbiol Infect"},{"key":"18_CR0018177","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.jacc.2008.12.038","volume":"53","author":"R Quarck","year":"2009","unstructured":"Quarck R, Nawrot T, Meyns B et al (2009) C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. J Am Coll Cardiol 53:1211\u20131218","journal-title":"J Am Coll Cardiol"},{"key":"18_CR0018178","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/0049-0172(84)90015-5","volume":"13","author":"FP Quismorio Jr","year":"1984","unstructured":"Quismorio FP Jr, Sharma O, Koss M et al (1984) Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. Semin Arthritis Rheum 13:349\u2013359","journal-title":"Semin Arthritis Rheum"},{"key":"18_CR0018179","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMra050541","volume":"353","author":"T Rhen","year":"2005","unstructured":"Rhen T, Cidlowski JA (2005) Antiinflammatory action of glucocorticoids \u2013 new mechanisms for old drugs. N Engl J Med 353:1711\u20131723","journal-title":"N Engl J Med"},{"key":"18_CR0018180","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/014107680109400110","volume":"94","author":"JM Ribeiro","year":"2001","unstructured":"Ribeiro JM, Lucas M, Victorino RM (2001) Remission of precapillary pulmonary hypertension in systemic lupus erythematosus. J R Soc Med 94:32\u201333","journal-title":"J R Soc Med"},{"key":"18_CR0018181","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/S0735-1097(86)80301-1","volume":"8","author":"S Rich","year":"1986","unstructured":"Rich S, Kieras K, Hart K et al (1986) Antinuclear antibodies in primary pulmonary hypertension. J Am Coll Cardiol 8:1307\u20131311","journal-title":"J Am Coll Cardiol"},{"key":"18_CR0018182","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1056\/NEJMra012396","volume":"346","author":"AG Ross","year":"2002","unstructured":"Ross AG, Bartley PB, Sleigh AC et al (2002) Schistosomiasis. N Engl J Med 346:1212\u20131220","journal-title":"N Engl J Med"},{"key":"18_CR0018183","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJM199701093360207","volume":"336","author":"LJ Rubin","year":"1997","unstructured":"Rubin LJ (1997) Primary pulmonary hypertension. N Engl J Med 336:111\u2013117","journal-title":"N Engl J Med"},{"key":"18_CR0018184","doi-asserted-by":"crossref","unstructured":"Ryan J, Bloch K, Archer SL (2011) Rodent models of pulmonary hypertension: harmonisation with the world health organisation\u2019s categorisation of human PH. Int J Clin Pract Suppl (172):15\u201334","DOI":"10.1111\/j.1742-1241.2011.02710.x"},{"key":"18_CR0018185","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1128\/cdli.4.5.519-521.1997","volume":"4","author":"KV Salojin","year":"1997","unstructured":"Salojin KV, Bordron A, Nassonov EL et al (1997) Anti-endothelial cell antibody, thrombomodulin, and von Willebrand factor in idiopathic inflammatory myopathies. Clin Diagn Lab Immunol 4:519\u2013521","journal-title":"Clin Diagn Lab Immunol"},{"key":"18_CR0018186","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1378\/chest.130.1.182","volume":"130","author":"O Sanchez","year":"2006","unstructured":"Sanchez O, Sitbon O, Jais X et al (2006) Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 130:182\u2013189","journal-title":"Chest"},{"key":"18_CR0018187","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1164\/rccm.200610-1559OC","volume":"176","author":"O Sanchez","year":"2007","unstructured":"Sanchez O, Marcos E, Perros F et al (2007) Role of endothelium-derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 176:1041\u20131047","journal-title":"Am J Respir Crit Care Med"},{"key":"18_CR0018188","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1465-9921-10-6","volume":"10","author":"L Savale","year":"2009","unstructured":"Savale L, Tu L, Rideau D et al (2009) Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir Res 10:6","journal-title":"Respir Res"},{"key":"18_CR0018189","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/347669a0","volume":"347","author":"TJ Schall","year":"1990","unstructured":"Schall TJ, Bacon K, Toy KJ et al (1990) Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 347:669\u2013671","journal-title":"Nature"},{"key":"18_CR0018190","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1084\/jem.177.6.1821","volume":"177","author":"TJ Schall","year":"1993","unstructured":"Schall TJ, Bacon K, Camp RD et al (1993) Human macrophage inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta chemokines attract distinct populations of lymphocytes. J Exp Med 177:1821\u20131826","journal-title":"J Exp Med"},{"key":"18_CR0018191","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1172\/JCI24838","volume":"115","author":"RT Schermuly","year":"2005","unstructured":"Schermuly RT, Dony E, Ghofrani HA et al (2005) Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115:2811\u20132821","journal-title":"J Clin Invest"},{"key":"18_CR0018192","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1161\/CIRCULATIONAHA.110.944603","volume":"122","author":"BG Schwartz","year":"2010","unstructured":"Schwartz BG, Kloner RA (2010) Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension. Circulation 122:88\u201395","journal-title":"Circulation"},{"key":"18_CR0018193","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.105.611350","volume":"113","author":"BM Scirica","year":"2006","unstructured":"Scirica BM, Morrow DA (2006) Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation 113:2128\u20132134, discussion 2151","journal-title":"Circulation"},{"key":"18_CR0018194","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1002\/1529-0131(200011)43:11<2550::AID-ANR24>3.0.CO;2-H","volume":"43","author":"R Sgonc","year":"2000","unstructured":"Sgonc R, Gruschwitz MS, Boeck G et al (2000) Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum 43:2550\u20132562","journal-title":"Arthritis Rheum"},{"issue":"Pt 2","key":"18_CR0018195","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1042\/bj3020551","volume":"302","author":"F Shibasaki","year":"1994","unstructured":"Shibasaki F, Fukami K, Fukui Y et al (1994) Phosphatidylinositol 3-kinase binds to alpha-actinin through the p85 subunit. Biochem J 302(Pt 2):551\u2013557","journal-title":"Biochem J"},{"key":"18_CR0018196","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/j.jacc.2009.04.012","volume":"54","author":"G Simonneau","year":"2009","unstructured":"Simonneau G, Robbins IM, Beghetti M et al (2009) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54:S43\u2013S54","journal-title":"J Am Coll Cardiol"},{"key":"18_CR0018197","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1164\/rccm.200704-541OC","volume":"177","author":"O Sitbon","year":"2008","unstructured":"Sitbon O, Lascoux-Combe C, Delfraissy JF et al (2008) Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 177:108\u2013113","journal-title":"Am J Respir Crit Care Med"},{"key":"18_CR0018198","doi-asserted-by":"publisher","first-page":"H677","DOI":"10.1152\/ajpheart.91519.2007","volume":"295","author":"Y Song","year":"2008","unstructured":"Song Y, Coleman L, Shi J et al (2008) Inflammation, endothelial injury, and persistent pulmonary hypertension in heterozygous BMPR2-mutant mice. Am J Physiol Heart Circ Physiol 295:H677\u2013H690","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"18_CR0018199","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1161\/CIRCULATIONAHA.109.933762","volume":"122","author":"E Soon","year":"2010","unstructured":"Soon E, Holmes AM, Treacy CM et al (2010) Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 122:920\u2013927","journal-title":"Circulation"},{"key":"18_CR0018200","first-page":"57S","volume":"122","author":"R Speich","year":"2000","unstructured":"Speich R, Boehler A, Rochat T et al (2000) Cystic fibrosis: current therapy. Indications for lung transplantation. Schweiz Med Wochenschr Suppl 122:57S\u201358S","journal-title":"Schweiz Med Wochenschr Suppl"},{"key":"18_CR0018201","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/clpt.2010.120","volume":"88","author":"R Spence","year":"2010","unstructured":"Spence R, Mandagere A, Richards DB et al (2010) Potential for pharmacokinetic interactions between ambrisentan and cyclosporine. Clin Pharmacol Ther 88:513\u2013520","journal-title":"Clin Pharmacol Ther"},{"key":"18_CR0018202","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.semarthrit.2005.03.005","volume":"35","author":"VD Steen","year":"2005","unstructured":"Steen VD (2005) Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 35:35\u201342","journal-title":"Semin Arthritis Rheum"},{"key":"18_CR0018203","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1161\/CIRCRESAHA.108.182014","volume":"104","author":"MK Steiner","year":"2009","unstructured":"Steiner MK, Syrkina OL, Kolliputi N et al (2009) Interleukin-6 overexpression induces pulmonary hypertension. Circ Res 104:236\u2013244, 228p following 244","journal-title":"Circ Res"},{"key":"18_CR0018204","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1191\/0961203303lu251oa","volume":"12","author":"L Stojanovich","year":"2003","unstructured":"Stojanovich L, Stojanovich R, Kostich V et al (2003) Neuropsychiatric lupus favourable response to low dose i.v. cyclophosphamide and prednisolone (pilot study). Lupus 12:3\u20137","journal-title":"Lupus"},{"key":"18_CR0018205","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s00109-011-0762-2","volume":"89","author":"G Sutendra","year":"2011","unstructured":"Sutendra G, Dromparis P, Bonnet S et al (2011) Pyruvate dehydrogenase inhibition by the inflammatory cytokine TNFalpha contributes to the pathogenesis of pulmonary arterial hypertension. J Mol Med (Berl) 89:771\u2013783","journal-title":"J Mol Med (Berl)"},{"key":"18_CR0018206","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.bbrc.2006.08.109","volume":"349","author":"C Suzuki","year":"2006","unstructured":"Suzuki C, Takahashi M, Morimoto H et al (2006) Mycophenolate mofetil attenuates pulmonary arterial hypertension in rats. Biochem Biophys Res Commun 349:781\u2013788","journal-title":"Biochem Biophys Res Commun"},{"key":"18_CR0018207","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1183\/09031936.00070209","volume":"35","author":"B Sztrymf","year":"2010","unstructured":"Sztrymf B, Souza R, Bertoletti L et al (2010) Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. Eur Respir J 35:1286\u20131293","journal-title":"Eur Respir J"},{"key":"18_CR0018208","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1136\/thx.2004.029082","volume":"60","author":"MC Tamby","year":"2005","unstructured":"Tamby MC, Chanseaud Y, Humbert M et al (2005) Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension. Thorax 60:765\u2013772","journal-title":"Thorax"},{"key":"18_CR0018209","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1183\/09031936.06.00152705","volume":"28","author":"MC Tamby","year":"2006","unstructured":"Tamby MC, Humbert M, Guilpain P et al (2006) Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension. Eur Respir J 28:799\u2013807","journal-title":"Eur Respir J"},{"key":"18_CR0018210","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1161\/CIRCRESAHA.110.236927","volume":"109","author":"R Tamosiuniene","year":"2011","unstructured":"Tamosiuniene R, Tian W, Dhillon G et al (2011) Regulatory T cells limit vascular endothelial injury and prevent pulmonary hypertension. Circ Res 109:867\u2013879","journal-title":"Circ Res"},{"key":"18_CR0018211","first-page":"282","volume":"29","author":"E Tanaka","year":"2002","unstructured":"Tanaka E, Harigai M, Tanaka M et al (2002) Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. J Rheumatol 29:282\u2013287","journal-title":"J Rheumatol"},{"key":"18_CR0018212","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1164\/rccm.200608-1189OC","volume":"175","author":"L Taraseviciene-Stewart","year":"2007","unstructured":"Taraseviciene-Stewart L, Nicolls MR, Kraskauskas D et al (2007) Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling. Am J Respir Crit Care Med 175:1280\u20131289","journal-title":"Am J Respir Crit Care Med"},{"key":"18_CR0018213","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1056\/NEJMoa055120","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Tashkin DP, Elashoff R, Clements PJ et al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:2655\u20132666","journal-title":"N Engl J Med"},{"key":"18_CR0018214","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1164\/rccm.200707-1015OC","volume":"177","author":"B Terrier","year":"2008","unstructured":"Terrier B, Tamby MC, Camoin L et al (2008) Identification of target antigens of antifibroblast antibodies in pulmonary arterial hypertension. Am J Respir Crit Care Med 177:1128\u20131134","journal-title":"Am J Respir Crit Care Med"},{"key":"18_CR0018215","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1136\/ard.2008.104299","volume":"69","author":"B Terrier","year":"2009","unstructured":"Terrier B, Tamby MC, Camoin L et al (2009) Antifibroblast antibodies from systemic sclerosis patients bind to {alpha}-enolase and are associated with interstitial lung disease. Ann Rheum Dis 69:428\u2013433","journal-title":"Ann Rheum Dis"},{"key":"18_CR0018216","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1046\/j.1365-2796.1997.00191.x","volume":"242","author":"R Thurnheer","year":"1997","unstructured":"Thurnheer R, Jenni R, Russi EW et al (1997) Hyperthyroidism and pulmonary hypertension. J Intern Med 242:185\u2013188","journal-title":"J Intern Med"},{"key":"18_CR0018217","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1161\/01.CIR.0000084544.54513.E2","volume":"108","author":"A Torbicki","year":"2003","unstructured":"Torbicki A, Kurzyna M, Kuca P et al (2003) Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation 108:844\u2013848","journal-title":"Circulation"},{"key":"18_CR0018218","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1016\/j.lpm.2010.11.004","volume":"40","author":"O Torre","year":"2011","unstructured":"Torre O, Harari S (2011) Pleural and pulmonary involvement in systemic lupus erythematosus. Presse Med 40:e19\u2013e29","journal-title":"Presse Med"},{"key":"18_CR0018219","doi-asserted-by":"publisher","first-page":"e31465","DOI":"10.1371\/journal.pone.0031465","volume":"7","author":"K Tsuda","year":"2012","unstructured":"Tsuda K, Yamanaka K, Kitagawa H et al (2012) Calcineurin inhibitors suppress cytokine production from memory T cells and differentiation of naive T cells into cytokine-producing mature T cells. PLoS One 7:e31465","journal-title":"PLoS One"},{"key":"18_CR0018220","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1055\/s-0029-1233307","volume":"30","author":"RM Tuder","year":"2009","unstructured":"Tuder RM (2009) Pathology of pulmonary arterial hypertension. Semin Respir Crit Care Med 30:376\u2013385","journal-title":"Semin Respir Crit Care Med"},{"key":"18_CR0018221","first-page":"275","volume":"144","author":"RM Tuder","year":"1994","unstructured":"Tuder RM, Groves B, Badesch DB et al (1994) Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 144:275\u2013285","journal-title":"Am J Pathol"},{"key":"18_CR0018222","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1136\/ard.2009.114264","volume":"69","author":"AJ Tyndall","year":"2010","unstructured":"Tyndall AJ, Bannert B, Vonk M et al (2010) Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69:1809\u20131815","journal-title":"Ann Rheum Dis"},{"key":"18_CR0018223","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1159\/000111548","volume":"75","author":"S Ulrich","year":"2008","unstructured":"Ulrich S, Nicolls MR, Taraseviciene L et al (2008a) Increased regulatory and decreased CD8+ cytotoxic T cells in the blood of patients with idiopathic pulmonary arterial hypertension. Respiration 75:272\u2013280","journal-title":"Respiration"},{"key":"18_CR0018224","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1465-9921-9-20","volume":"9","author":"S Ulrich","year":"2008","unstructured":"Ulrich S, Taraseviciene-Stewart L, Huber LC et al (2008b) Peripheral blood B lymphocytes derived from patients with idiopathic pulmonary arterial hypertension express a different RNA pattern compared with healthy controls: a cross sectional study. Respir Res 9:20","journal-title":"Respir Res"},{"key":"18_CR0018225","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1365-2613.2006.00493.x","volume":"87","author":"L Vajner","year":"2006","unstructured":"Vajner L, Vytasek R, Lachmanova V et al (2006) Acute and chronic hypoxia as well as 7-day recovery from chronic hypoxia affects the distribution of pulmonary mast cells and their MMP-13 expression in rats. Int J Exp Pathol 87:383\u2013391","journal-title":"Int J Exp Pathol"},{"key":"18_CR0018226","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1378\/chest.10-1200","volume":"139","author":"S Valmary","year":"2011","unstructured":"Valmary S, Dorfmuller P, Montani D et al (2011) Human gamma-herpesviruses Epstein-Barr virus and human herpesvirus-8 are not detected in the lungs of patients with severe pulmonary arterial hypertension. Chest 139:1310\u20131316","journal-title":"Chest"},{"key":"18_CR0018227","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1093\/rheumatology\/35.4.364","volume":"35","author":"FH van den Hoogen","year":"1996","unstructured":"van den Hoogen FH, Boerbooms AM, Swaak AJ et al (1996) Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 35:364\u2013372","journal-title":"Br J Rheumatol"},{"issue":"12","key":"18_CR0018228","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1177\/0091270011423662","volume":"52","author":"J Venitz","year":"2012","unstructured":"Venitz J, Zack J, Gillies H et al (2012) Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J Clin Pharmacol 52(12):1784\u20131805","journal-title":"J Clin Pharmacol"},{"key":"18_CR0018229","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s10875-009-9322-8","volume":"29","author":"W Wang","year":"2009","unstructured":"Wang W, Yan H, Zhu W et al (2009) Impairment of monocyte-derived dendritic cells in idiopathic pulmonary arterial hypertension. J Clin Immunol 29:705\u2013713","journal-title":"J Clin Immunol"},{"key":"18_CR0018230","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1007\/s11033-010-0390-x","volume":"38","author":"W Wang","year":"2011","unstructured":"Wang W, Wang YL, Chen XY et al (2011) Dexamethasone attenuates development of monocrotaline-induced pulmonary arterial hypertension. Mol Biol Rep 38:3277\u20133284","journal-title":"Mol Biol Rep"},{"key":"18_CR0018231","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jaci.2010.12.1087","volume":"127","author":"C Yildirim-Toruner","year":"2011","unstructured":"Yildirim-Toruner C, Diamond B (2011) Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol 127:303\u2013312, quiz 313\u2013304","journal-title":"J Allergy Clin Immunol"},{"key":"18_CR0018232","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.rmed.2007.07.021","volume":"102","author":"AC Zamora","year":"2008","unstructured":"Zamora AC, Wolters PJ, Collard HR et al (2008) Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med 102:150\u2013155","journal-title":"Respir Med"},{"key":"18_CR0018233","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00296-009-0966-8","volume":"30","author":"Y Zheng","year":"2010","unstructured":"Zheng Y, Li M, Zhang Y et al (2010) The effects and mechanisms of mycophenolate mofetil on pulmonary arterial hypertension in rats. Rheumatol Int 30:341\u2013348","journal-title":"Rheumatol Int"},{"key":"18_CR0018234","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1177\/0091270004273321","volume":"45","author":"H Zhou","year":"2005","unstructured":"Zhou H (2005) Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. J Clin Pharmacol 45:490\u2013497","journal-title":"J Clin Pharmacol"},{"key":"18_CR0018235","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1172\/JCI35180","volume":"118","author":"L Zitvogel","year":"2008","unstructured":"Zitvogel L, Apetoh L, Ghiringhelli F et al (2008) The anticancer immune response: indispensable for therapeutic success? J Clin Invest 118:1991\u20132001","journal-title":"J Clin Invest"}],"container-title":["Handbook of Experimental Pharmacology","Pharmacotherapy of Pulmonary Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-642-38664-0_18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T07:43:45Z","timestamp":1749023025000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-642-38664-0_18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"ISBN":["9783642386633","9783642386640"],"references-count":235,"aliases":["10.1007\/978-3-662-45805-1_18","10.1007\/978-3-662-45805-1_18"],"URL":"https:\/\/doi.org\/10.1007\/978-3-642-38664-0_18","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]},"assertion":[{"value":"6 August 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}